

Evaluating simple objective metrics for the remote measurement of physical activity: preliminary results from the RADAR-AD study



Marijn Muurling¹, Chris Hinds², Yuhao Wu², Alankar Aryal Atreya², Jelena Curcic³, Aiden Doherty², Pauline Conde⁴, Andrew Owens⁴, Casper de Boer¹, Dag Aarsland^{4,5}, Vaibhav Narayan⁶, Pieter Jelle Visser¹, and the RADAR-AD consortium 1. Alzheimer Center Amsterdam, the Netherlands; 2. University of Oxford, UK; 3. Novartis Institutes for Biomedical Research, Basel, Switzerland; 4. King's College London, UK; 5. Stavanger University Hospital, Norway; 6. Janssen Neuroscience Research & Development, USA









BACKGROUND

- Higher physical activity is associated with better global cognition and a lower risk of dementia (Rojer et al, 2021).
- Using questionnaires to assess physical activity is difficult in an Alzheimer's disease (AD) population, since questionnaires rely on retrospective subjective recall.
- Wearables measure physical activity passively, objectively and continuously, and are therefore expected to measure changes in physical activity more sensitively.

AIMS OF THE STUDY

- 1. To compare simple activity metrics from two activity trackers monitoring physical activity between different stages of Alzheimer's disease.
- 2. To relate these simple metrics to standard clinical questionnaires.

STUDY DESIGN

- During 8-weeks, participants wore 2 activity trackers (Axivity AX3 and Fitbit Charge 3). Scan the QR code on the top right to learn more about the design of the study.
- The Axivity gives raw acceleration data, which can be processed according to Doherty et al., 2017 to the following outcomes: acceleration magnitude, time spent in sedentary, light, moderate-to-vigorous activity, and sleeping
- The Fitbit gives processed data: step count and heart rate
- Standard questionnaires:
 - Global cognition (Mini-mental state examination, MMSE)
 - Self-reported activity levels (Godin Leisure Time Questionnaire, GLTQ)
 - Depression (Geriatric Depression Scale, GDS)
 - Partner-reported function (ADCS-ADL)
 - Neuropsychiatric symptoms (Neuropsychiatric Inventory, NPI-Q)

CDUID DIEEEDENICES

	GROUP DIFFERENCES									
, INESO		Healthy control	Preclinical AD	Prodromal AD	Mild-to- moderate AD	P-value				
) 1	n	44	17	23	17					
	Age	67 (7)	69 (7)	71 (7)	67 (10)	0.16				
	Female, n(%)	24 (55%)	13 (77%)	10 (44%)	9 (53%)	0.22				
	Education, y	15 (3)	15 (3)	14 (4)	13 (4)	0.17				
	Season, n					0.18				
	Spring	• 15	• 1	• 5	• 7					
	• Summer	• 13	• 6	• 9	• 5					
	Autumn	• 9	• 9	• 5	• 3					
	Winter	• 7	• 1	• 4	• 2					
	Standard questionnaires									
	MMSE, total	29 (1)	29 (1)	27 (2)	23 (3)	<0.01 ^{b,c,d,e,f}				
	GDS	1 (2)	2 (2)	3 (3)	3 (2)	<0.01 ^{a,b,c}				
	GLTQ	34 (25)	41 (33)	27 (20)	32 (27)	0.40				
	ADCS-ADL	76 (3)	76 (3)	72 (5)	64 (9)	<0.01 ^{b,c,d,e,f}				
	NPI-Q	1.2 (1)	1.9 (1.8)	2.6 (2.7)	9.5 (17)	<0.01 ^{c,e,f}				
	Activity trackers									
	Acc magnitude, mg	24 (5)	20 (6)	22 (9)	24 (9)	0.24*				
i	Sedentary, h/day	7.4 (1.5)	8.2 (1.2)	8.5 (2.4)	7.9 (2.2)	0.12*				
	Light activity, h/day	7.2 (1.5)	6.3 (1.5)	6.2 (2.3)	6.0 (2.4)	0.048*c				

0.4(0.3)

9.2 (1.1)

71 (8)

6980 (3318)

0.4(0.4)

9.0 (1.2)

68 (6)

6891 (4402)

Table 1: Numbers show mean(SD), unless specified otherwise. The season variable shows the number of participants started at: March to May (spring), June to August (summer), September to November (autumn), December to February (winter). Acc = acceleration,

0.4 (0.3)

9.0 (1.2)

72 (7)

7156 (3222)

				Fitbit				
		Acc magnitude	Sedentary h/day	Light activity h/day	MVPA h/day	Sleep h/day	Step count	Heart rate BPM
	Age	-0.3(0.09) p<0.001		-5.52(2.35) p=0.02		-2.01(1.54) p=0.19	-94.08(46.25) p=0.04	-0.11(0.09) p=0.23
	IVIIVISE	0.3(0.23) p=0.20		18.06(5.95) p=0.003	-0.27(1.15) p=0.82	-11.96(3.8) p=0.002	208.27(119.52) p=0.08	0.48(0.22) p=0.03
	GDS	-0.25(0.32) p=0.44	8.36(8.5) p=0.33	-13.77(8.25) p=0.10	-1.89(1.52) p=0.22	7.3(5.24) p=0.17	-184.19(166.5) p=0.27	-0.68(0.31) p=0.03
	GLIO	0.04(0.03) p=0.12	-1.06(0.72) p=0.14	1.21(0.73) p=0.10	0.31(0.13) p=0.02	-0.46(0.47) p=0.33	42.88(13.63) p=0.002	0(0.03) p=0.99
	ADCS-ADL	0.09(0.11) p=0.42	-5.36(2.87) p=0.07	7.81(2.79) p=0.01	0.28(0.52) p=0.59	-2.74(1.81) p=0.13	111.6(56.19) p=0.05	0.11(0.11) p=0.30
	NPEOMOTAL	0.07(0.09) p=0.47	` '	0.61(2.51) p=0.81	0.04(0.46) p=0.93	0.52(1.61) p=0.75	17.28(48.86) p=0.72	-0.14(0.09) p=0.12

Table 2: Numbers show beta (SE), p-value, uncorrected for age and sex. Acc = acceleration, MVPA = moderate-to-vigorous physical activity, BPM = beats per minute. See study design for other abbreviations.

0.73*

0.36*

0.99*

0.04*b,c

ASSOCIATIONS WITH STANDARD QUESTIONNAIRES

CONCLUSION

Number of steps, n

Mean heart rate, BPM

MVPA, h/day

Sleep, h/day

Group differences were found for time spent in light activity and heart rate, but these differences were very minimal.

0.5 (0.4)

9.6 (1.3)

68 (6)

7264 (4379)

- Higher physical activity as measured with wearables is associated with lower age and higher global cognition. Self-reported activity is associated with moderate-to-vigorous activity and step count.
- On-going research in the RADAR-AD study will focus on developing disease-specific methods of feature extraction based on raw movement data, and combining features from multiple devices, to explore this further.

^{*} Linear models corrected for age and sex.

a,b,c,d,e,f Significant difference between a) healthy control and preclinical AD, b) healthy control and prodromal AD, c) healthy control and mild-to-BPM = beats per minute, mg = milligravity, MVPA = moderate-to-vigorous physical activity. moderate AD, d) preclinical AD and mild-to-moderate AD, d) precl